Literature DB >> 6859228

Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.

R Huey, C M Bloor, M S Kawahara, T E Hugli.   

Abstract

Carboxypeptidase N (EC 3.4.12.7) (SCPN) is a plasma enzyme that efficiently inactivates the anaphylatoxins C3a and C4a and significantly reduces C5a spasmogenic activity by removing the C-terminal arginyl residue from each of these factors. The arginine analog DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (SCPN-INH) is a potent competitive inhibitor of SCPN with a Ki for this carboxypeptidase in serum of 2 x 10(-9) M. Therefore, we have used the SCPN inhibitor to potentiate biologic activity of the anaphylatoxins in vivo. Infusion via the carotid artery of about 40 mg of SCPN-INH into each of 8 adult guinea pigs inactivated the SCPN for at least 3 hours and caused no measurable toxic effects. When cobra venom factor (CVF) is infused into guinea pigs, it activates the alternative pathway of complement, thereby generating the anaphylatoxins C3a and C5a. Ordinarily, infusion of CVF is nonlethal, because the generated anaphylatoxins are rapidly converted to C3a des Arg and C5a des Arg by SCPN. However, CVF (200 micrograms) plus SCPN-INH delivered intravenously in 5 animals induced a lethal reaction in less than 5 minutes. The authors conclude that the lethal effect is due largely to the anaphylatoxins. Histologic sections of the lungs from treated animals show dramatic structural changes consistent with peripheral small airway constriction, bronchial constriction, and vasoconstriction of small muscular arteries. Also, cell aggregates are present in blood vessels. Other histologic changes include severe congestion, pulmonary edema, and an interstitial infiltrate of mononuclear cells. Large doses of chlorpheniramine prevent this lethal reaction. Lethality is apparently attributable to asphyxia and is dependent on the level of CVF administered: eg, 100 micrograms CVF was not lethal in 4 animals given SCPN inhibitor, although signs of respiratory distress were observed. On histologic examination of lungs from guinea pigs given CVF and SCPN-INH, the features are similar to those described when anaphylatoxins are instilled into guinea pig lungs. Intravenous application of purified C3a plus SCPN-INH also proved lethal in 3 of the 6 animals challenged. This is the first evidence that the C3a anaphylatoxin can elicit a lethal response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6859228      PMCID: PMC1916315     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms.

Authors:  P A Ward; H F Dvorak; S Cohen; T Yoshida; R Data; S S Selvaggio
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

2.  Anaphylatoxin from the fifth component of porcine complement. Purification and partial chemical characterization.

Authors:  C Gerard; T E Hugli
Journal:  J Biol Chem       Date:  1979-07-25       Impact factor: 5.157

3.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

4.  Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.

Authors:  H J Müller-Eberhard; K E Fjellström
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

Review 5.  Immune complex injury of the lung. Symposium held at the 74th annual meeting of the American Thoracic Society, Las Vegas, Nevada, May 1979.

Authors:  R P Daniele; P M Henson; J C Fantone; P A Ward; R B Dreisin
Journal:  Am Rev Respir Dis       Date:  1981-12

6.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

7.  Isolation of three separate anaphylatoxins from complement-activated human serum.

Authors:  T E Hugli; C Gerard; M Kawahara; M E Scheetz; R Barton; S Briggs; G Koppel; S Russell
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

8.  Inhibition of C5 convertase by epsilon amino caproic acid (EACA): a limiting factor in the generation of C5a anaphylatoxin.

Authors:  E H Vallota
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

9.  Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils.

Authors:  G Camussi; J M Mencia-Huerta; J Benveniste
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

10.  Antigen-induced release of slow reacting substance of anaphylaxis (SRS-A rat) in rats prepared with homologous antibody.

Authors:  R P Orange; M D Valentine; K F Austen
Journal:  J Exp Med       Date:  1968-04-01       Impact factor: 14.307

View more
  17 in total

1.  Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.

Authors:  Mercy O Quagraine; Fulong Tan; Hironori Tamei; Ervin G Erdös; Randal A Skidgel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

2.  Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release.

Authors:  E S Schulman; T J Post; P M Henson; P C Giclas
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

3.  Mechanism of action of the group A streptococcal C5a inactivator.

Authors:  D E Wexler; D E Chenoweth; P P Cleary
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.

Authors:  T Hoffmann; E C Böttger; H P Baum; M Messner; U Hadding; D Bitter-Suermann
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

5.  Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements.

Authors:  R Gerardy-Schahn; D Ambrosius; M Casaretto; J Grötzinger; D Saunders; A Wollmer; D Brandenburg; D Bitter-Suermann
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

Review 7.  Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Int Immunopharmacol       Date:  2007-08-15       Impact factor: 4.932

8.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

9.  Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.

Authors:  G O Till; M L Morganroth; R Kunkel; P A Ward
Journal:  Am J Pathol       Date:  1987-10       Impact factor: 4.307

10.  Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency.

Authors:  K P Mathews; J G Curd; T E Hugli
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.